CoChat

Self-immolative Linkers in Prodrugs and Antibody Drug Conjugates in Cancer Treatment

Edupuganti, Veera V. Shivaji R., Tyndall, Joel D.A., Gamble, Allan B. · 2021 · Recent Patents on Anti-Cancer Drug Discovery

The DOI matches its Crossref record; 68 of the 90 references it cites were found in a registry or an index.

Abstract

Background: The design of anti-cancer therapies with high anti-tumour efficacy and reduced toxicity continues to be challenging. Anti-cancer prodrug and antibody-drug-conjugate (ADC) strategies that can specifically and efficiently deliver cytotoxic compounds to cancer cells have been used to overcome some of the challenges. The key to the success of many of these strategies is a self-immolative linker, which after activation can release the drug payload. Various types of triggerable self-immolative linkers are used in prodrugs and ADCs to improve their efficacy and safety. Objective: Numerous patents have reported the significance of self-immolative linkers in prodrugs and ADCs in cancer treatment. Based on the recent patent literature, we summarise methods for designing the site-specific activation of non-toxic prodrugs and ADCs in order to improve selectivity for killing cancer cells. Methods: In this review, an integrated view of the potential use of prodrugs and ADCs in cancer treatment are provided. This review presents recent patents and related publications over the past ten years uptill 2020. Results: The recent patent literature has been summarised for a wide variety of self-immolative PABC linkers, which are cleaved by factors including responding to the difference between the extracellular and intracellular environments (pH, ROS, glutathione) through over-expressed enzymes (cathepsin, plasmin, β-glucuronidase) or bioorthogonal activation. The mechanism for self-immolation involves the linker undergoing a 1,4- or 1,6-elimination (via electron cascade) or intramolecular cyclisation to release cytotoxic drug at the targeted site. Conclusion: This review provides the commonly used strategies from recent patent literature in the development of prodrugs based on targeted cancer therapy and antibody-drug conjugates, which show promise in therapeutic applications.

Overview

Integrity signals

Registry

Crossref · 10.2174/1574892816666210509001139

Cites

68 of 68 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Citations

Cites

Show all 68 references

Cited by

See all 37

Metadata

Authors
Edupuganti, V. V. S. R., Tyndall, J. D. A., & Gamble, A. B.
Affiliations
  • School of Pharmacy, University of Otago, Dunedin 9054,New Zealand
  • University of Otago (NZ)
Corresponding author
  • Tyndall, Joel D.A.
  • Gamble, Allan B.
Venue
Recent Patents on Anti-Cancer Drug Discovery
Published
2021-11
Volume
16
Issue
4
Pages
479-497
ISSN
1574-8928 (ISSN-L)
OpenAlex
W3161294989
Cited by
36
References
90
Citations by year
2026: 11 · 2025: 13 · 2024: 4 · 2023: 6 · 2022: 2
FWCI
0.21
Type
journal article
Language
en
Open access
closed
Locations
  • Recent Patents on Anti-Cancer Drug Discovery (publishedVersion)
  • PubMed (publishedVersion)
  • Otago University Research Archive (University of Otago) (acceptedVersion)
Topics
  • Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
  • Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
  • Physical Sciences › Chemistry › Organic Chemistry › Synthesis and pharmacology of benzodiazepine derivatives
Keywords
self-immolative linker, prodrugs, antibody-drug conjugates, cancer therapy, reactive oxygen species, glutathione, plasmin, beta-glucuronidase, 1,4-elimination, 1,6-elimination, intramolecular cyclization, targeted cancer therapy
MeSH terms
Antineoplastic Agents, Humans, Neoplasms, Patents as Topic, Prodrugs, Drug Design, Drug Delivery Systems, Immunoconjugates, Cell Line, Tumor, Drug Liberation

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Self-immolative Linkers in Prodrugs and Antibody Drug Conjugates in Cancer Treatment. https://app.cochat.ai/papers/10.2174/1574892816666210509001139
The paper
Edupuganti, V. V. S. R., Tyndall, J. D. A., & Gamble, A. B. (2021). Self-immolative Linkers in Prodrugs and Antibody Drug Conjugates in Cancer Treatment. Recent Patents on Anti-Cancer Drug Discovery. https://doi.org/10.2174/1574892816666210509001139

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.